Michael D. Prados, MD

Mississippi State University, Starkville, 1966-1969, Biology
University of New Orleans, BS, 1969-1970, Biology
LSU School of Medicine, MD, 1970-1974, Medicine
LSU Charity Hospital, New Orleans, LA, Internship, 1974-1975, Medicine
LSU Earl K Long Hospital, Baton Rouge, LA, Residency, 1975-1977, Internal Medicine

• 1977-1978
  Instructor, Department of Internal Medicine, LSU School of Medicine, New Orleans, LA
• 1979-1982
  Assistant Professor, Department of Medicine, LSU School of Medicine, Earl K Long Hospital, Baton Rouge, LA
• 1980-1982
  Clinical Director, Medical Oncology, Dept. of Medicine, LSU School of Medicine, Earl K Long Hospital, Baton Rouge, LA
• 1983-1984
  Pulmonary Fellowship (12 months), Tulane University School of Medicine, New Orleans, LA
• 1984-1985
  Asst. Clinical Director, Dept. of Pulmonary Medicine, Touro Infirmary, New Orleans, LA
• 1985-1987
  Clinical Instructor, Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, University of California, San Francisco, CA
• 1988-1991
  Asst. Clinical Prof., Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, School of Medicine, University of California, San Francisco, CA
• 1988-1989
  Acting Director, Neuro-Oncology Program, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco
• 1989-2005
  Director, Neuro-Oncology Program, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco
• 1991-1995
  Assoc. Clinical Professor, Chief, Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, School of Medicine, University of California, San Francisco, CA
• 1995-present
  Professor in Residence, Dept. of Neurological Surgery, University of California, San Francisco
• 2001-present
  Charles B. Wilson Professor of Neurological Surgery, University of California, San Francisco
• 2005 - present
  Director of the Translational Research Program in Neuro-Oncology, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco

• Wen PW, Yung WKA, Lamborn KR, Norden AD, Cloughesy TF, De Angelis LM, Fine HA, Chang SM, Robins IH, Fink K, Abrey LE, Lassman AB, Mehta M, Drappatz J, Kesari S, Di Tomaso ED, Ligon K, Aldape K, Jain R, Capdeville R, Stiles C, Kaplan R, Ergin MJ, Murgo AT, Prados MD: Phase II Study of Imatinib Mesylate (Gleevec®) For Recurrent Meningiomas (North American Brain Tumor Consortium Study 01-08). Neuro-Oncology 11 (6): 853-860, 2009 PMID 19293394; PMCID: PMC2802405.
• Prados MD, Chang SM, Butowski N, Burton E, DeBoer BA, Parvataneni R, Kivett V, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Federoff A, Sneed P, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27 (4): 579-584, 2009 PMID 19075262; PMCID: PMC2645859.
• Wiemals JL, Wilson D, Patel C, Patoka J, McCoy L, Rice T, Schwartzbaum J, Heimberger A, Chang S, Prados M, Wiencke JK, Wrensch M: IgE, Allergy, and Risk of Glioma: Update from the San Francisco Area Adult Glioma Study. International Journal of Cancer 125 (3): 680-687, 2009 PMID 19408307; NIHMS96660.
• Chang S, Nelson S, Vandenberg S, Cha C, Prados M, Butowski N, McDermott M, Parsa A, Aghi M, Clarke J, Berger M: Integration of preoperative anatomic and metabolic physiological imaging of newly diagnosed GBM. J of Neuro-Oncol 92: 401-415, 2009 PMID 19357966; NIHMS177631.
• Allen J, Donahue B, Mehta M, Miller DC, Rorke LB, Jakacki R, Robertson P, Sposto R, Holmes E, Vezina G, Muraszko K, Puccetti D, Prados M, Chan KW. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931). Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1006-11. Epub 2009 Apr 7. PMID: 19356859; PMCID: PMC2739055.
• Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, Ballman KV, Berger M, Buckner JC, Chang S, Giannini C, Halder C, Kollmeyer TM, Kosel ML, Lachance DH, McCoy L, O’Neill BP, Patoka J, Pico AR, Prados M, Quesenberry C, Rice T, Rynearson Al, Smirnov I, Tihan T, Weimels J, Yang P, Wiencke JK: Variants in the CDKN2B and RTEL 1 regions are associated with high-grade Glioma susceptibility. Nat Genet 41 (8): 905-908, 2009 PMID 19578366; NIHMS122986.
• McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA: Activation of the PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neuro-Oncology 2009 Aug 25 [Epub ahead of print] PMID 19705067; PMCID: PMC2814032.
• Hashizume R, Ozawa T, Dinca EB, Banerjee A, Prados MD, James CD, Gupta N: A human brainstem glioma xenograft model enabled for bioluminescence imaging. J of Neuro-Oncology 96 (2): 151-159, 2010 PMID: 19585223; PMCID: PMC2808534.
• Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman F: Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology 13 (6): 660-668, 2011. PMID:21558074 [PubMed - in process] PMCID: PMC3107095 [Available on 2012/6/1]